These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 31069554

  • 1. Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.
    Ali YM, Sweeney J, Shen P, Votanopoulos KI, McQuellon R, Duckworth K, Perry KC, Russell G, Levine EA.
    Ann Surg Oncol; 2020 Jan; 27(1):117-123. PubMed ID: 31069554
    [Abstract] [Full Text] [Related]

  • 2. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C, Bijelic L, Sugarbaker PH.
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [Abstract] [Full Text] [Related]

  • 3. Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Dodson RM, McQuellon RP, Mogal HD, Duckworth KE, Russell GB, Votanopoulos KI, Shen P, Levine EA.
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):772-783. PubMed ID: 27638671
    [Abstract] [Full Text] [Related]

  • 4. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA, RENAPE Working Group.
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [Abstract] [Full Text] [Related]

  • 5. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin.
    Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JH, Levine EA.
    Ann Surg Oncol; 2011 Dec; 18(13):3673-9. PubMed ID: 21674272
    [Abstract] [Full Text] [Related]

  • 6. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M.
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [Abstract] [Full Text] [Related]

  • 7. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
    Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, Zureikat AH, Holtzman MP, Pingpank J, Ahrendt S, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
    [Abstract] [Full Text] [Related]

  • 8. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V, Sleightholm RL, Rusthoven CG, Koshy M, Sher DJ, Grover S, Simone CB.
    Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
    [Abstract] [Full Text] [Related]

  • 9. Impairments in Bowel Function, Social Function and Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Bayat Z, Taylor EL, Bischof DA, McCart JA, Govindarajan A.
    Ann Surg Oncol; 2020 Jan; 27(1):124-131. PubMed ID: 31073912
    [Abstract] [Full Text] [Related]

  • 10. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
    Manzanedo I, Pereira F, Rihuete Caro C, Pérez-Viejo E, Serrano Á, Gutiérrez Calvo A, Regueira FM, Casado-Adam Á, Cascales-Campos PA, Arteaga X, García-Fadrique A, Gómez Sanz R, López García A, Zozaya G, Arjona Á, Gil Martínez J.
    Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
    [Abstract] [Full Text] [Related]

  • 11. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X, Li Z, Li Z, Jia Y, Shan F, Ji X, Bu Z, Zhang L, Wu A, Ji J.
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [Abstract] [Full Text] [Related]

  • 12. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC, Khashab T, Terhune J, Eckert RL, Hanna N, Burke A, Richard Alexander H.
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [Abstract] [Full Text] [Related]

  • 13. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?
    Hotopp T.
    Surg Oncol; 2019 Mar; 28():159-166. PubMed ID: 30851894
    [Abstract] [Full Text] [Related]

  • 14. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M, RENAPE Network.
    Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
    [Abstract] [Full Text] [Related]

  • 15. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
    Mercier F, Passot G, Villeneuve L, Levine EA, Yonemura Y, Goéré D, Sugarbaker PH, Marolho C, Bartlett DL, Glehen O, BIG-RENAPE Working Group.
    Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for patients at High-Risk of Peritoneal Metastases.
    Morris MC, Dhar VK, Stevenson MA, Winer LK, Lee TC, Wang J, Ahmad SA, Patel SH, Sussman JJ, Abbott DE.
    Surg Oncol; 2019 Dec; 31():33-37. PubMed ID: 31518971
    [Abstract] [Full Text] [Related]

  • 17. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
    Cornali T, Sammartino P, Kopanakis N, Christopoulou A, Framarino Dei Malatesta M, Efstathiou E, Spagnoli A, Ciardi A, Biacchi D, Spiliotis J.
    Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    Yu P, Ye Z, Dai G, Zhang Y, Huang L, Du Y, Cheng X.
    BMC Cancer; 2020 Nov 16; 20(1):1108. PubMed ID: 33198674
    [Abstract] [Full Text] [Related]

  • 19. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M.
    Ann Surg Oncol; 2016 May 16; 23(5):1468-73. PubMed ID: 26572754
    [Abstract] [Full Text] [Related]

  • 20. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y, Aycart S, Mandeli JP, Heskel M, Sarpel U, Labow DM.
    Surg Oncol; 2015 Sep 16; 24(3):264-9. PubMed ID: 26143715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.